ABL Bio to Present Posters on ABL206 and ABL209 at AACR

ABL Bio, a company specializing in bispecific antibodies, announced on March 19 that it will present preclinical data on ABL206 (NEOK001) and ABL209 (NEOK002) in a poster session at the American Association for Cancer Research (AACR) Annual Meeting.

The AACR Annual Meeting is an event where pharmaceutical and biotech companies, researchers, healthcare professionals, and patients from around the world gather to share the latest research achievements. This year, it is scheduled to take place from April 17 to 22 (local time) at the San Diego Convention Center in California, United States.

ABL206 (NEOK001) and ABL209 (NEOK002), which will be introduced through posters at this event, are bispecific antibody ADC pipelines developed by ABL Bio. NEOK Bio, which holds the clinical and global development rights to both pipelines, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for Phase 1 clinical trials and is rapidly moving forward with clinical development. ABL206 (NEOK001) targets both B7-H3 and ROR1 simultaneously, while ABL209 (NEOK002) targets EGFR and MUC1. Both pipelines utilize a payload based on a Topoisomerase I inhibitor.

The posters for ABL206 (NEOK001) and ABL209 (NEOK002) are scheduled to be released at the "Antibody-Drug Conjugates and Linker Engineering 2" session on April 20 (local time) next month.

According to the abstract, in preclinical studies, ABL206 (NEOK001) demonstrated improved efficacy and safety in both in vitro and in vivo models compared to single-antibody ADCs targeting ROR1 or B7-H3. In GLP toxicology studies involving non-human primates, generally favorable tolerability was also observed. ABL209 (NEOK002) showed strong anticancer activity and was found to mitigate EGFR-related toxicity.

ABL Bio CEO Sanghoon Lee stated, "ABL206 (NEOK001) and ABL209 (NEOK002) are next-generation ADC pipelines with promising preclinical data. The clinical development of both pipelines is being led by NEOK Bio in the United States. NEOK Bio has established an optimal clinical strategy with ADC development experts and aims to announce initial Phase 1 clinical data in 2027. Separately, ABL Bio is also actively conducting research on next-generation ADCs to follow ABL206 (NEOK001) and ABL209 (NEOK002), and we will accelerate R&D efforts to unveil subsequent pipelines as soon as possible."

This content was produced with the assistance of AI translation services.